GlassScriptPhysician profile
Jennifer Kim
NPI 1598314254
$7,213.36
in general payments reported to CMS, 2019-2025
51 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.96 · 2022: $1,022 · 2023: $2,497 · 2024: $2,304 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,158.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.15 | 2022-2025 | |
| Pfizer INC. | $429.51 | 2023-2025 | |
| Lundbeck LLC | $363.54 | 2022-2025 | Vyepti, Rexulti |
| Biogen, INC. | $362.07 | 2022-2025 | Vumerity, Tysabri, Plegridy |
| Neurelis, INC. | $319.10 | 2022-2025 | Valtoco |
| Lilly USA, LLC | $316.62 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Sk Life Science, INC. | $308.38 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $304.59 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $243.13 | 2022-2025 | Rystiggo, Zilbrysq |
| Alnylam Pharmaceuticals INC. | $242.58 | 2022-2024 | Onpattro, Amvuttra |
| Teva Pharmaceuticals USA, INC. | $224.51 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Argenx US, INC. | $218.62 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Otsuka America Pharmaceutical, INC. | $195.67 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $184.54 | 2023-2025 | Hyqvia, Trintellix |
| Amneal Pharmaceuticals LLC | $170.15 | 2022-2025 | Rytary, Lyvispah, Crexont |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.